At the time of writing, Halozyme Therapeutics Inc [HALO] stock is trading at $54.43, up 0.02%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HALO shares have gain 1.83% over the last week, with a monthly amount drifted -10.14%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on May 14, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $62 for it. Previously, Leerink Partners downgraded its rating to Underperform on May 13, 2025, and kept the price target unchanged to $47. On October 07, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $62 on the stock. JP Morgan downgraded its rating to a Neutral and increased its price target to $57 on September 19, 2024. Piper Sandler downgraded its rating to a Neutral and raised its price target to $51 on June 07, 2024. TD Cowen started tracking with a Outperform rating for this stock on February 29, 2024, and assigned it a price target of $54. In a note dated July 24, 2023, H.C. Wainwright initiated an Buy rating and provided a target price of $61 on this stock.
For the past year, the stock price of Halozyme Therapeutics Inc fluctuated between $42.01 and $70.50. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $54.43 at the most recent close of the market. An investor can expect a potential return of 13.91% based on the average HALO price forecast.
Analyzing the HALO fundamentals
According to Halozyme Therapeutics Inc [NASDAQ:HALO], the company’s sales were 1.08B for trailing twelve months, which represents an 35.22% jump. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.55%, Pretax Profit Margin comes in at 0.56%, and Net Profit Margin reading is 0.45%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 1.22 and Total Capital is 0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.07 points at the first support level, and at 53.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.94, and for the 2nd resistance point, it is at 55.45.
Ratios To Look Out For
It is important to note that Halozyme Therapeutics Inc [NASDAQ:HALO] has a current ratio of 8.39. As well, the Quick Ratio is 7.30, while the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 6.19, the price to book ratio is 13.90 and price to earnings (TTM) ratio is 14.44.
Transactions by insiders
Recent insider trading involved Henderson Jeffrey William, Director, that happened on Apr 28 ’25 when 4497.0 shares were sold. Director, Henderson Jeffrey William completed a deal on Apr 01 ’25 to sell 503.0 shares. Meanwhile, Director Henderson Jeffrey William sold 5000.0 shares on Mar 03 ’25.
